ALX-804-296-C100

antibody from Enzo Life Sciences

Targeting: TNFSF10 Apo-2L, CD253, TL2, TRAIL

Immunocytochemistry (Supportive data in Antibodypedia)

Flow cytometry (Data presented on provider website)

Functional assay (Data presented on provider website)

Antibody Data

Product number

ALX-804-296-C100

Provider

Enzo Life Sciences

Proper citation

Enzo Life Sciences Cat#ALX-804-296-C100, RRID:AB_2052719

Product name

TRAIL (human) monoclonal antibody (2E5)

Antibody type

Monoclonal

Antigen

Recombinant protein fragment

Description

Protein A-affinity purified. Sterile filtered.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

2E5

Vial size

100 μg

Storage

-20°C

Handling

Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20¡C.

References

Submitted references

Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.

Oh YT, Deng J, Yue P, Owonikoko TK, Khuri FR, Sun SY
Oncogene 2016 Jan 28;35(4):459-67

---

IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells.

Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D, Todeschini G, Pilla L, Martinelli G, Pizzolo G, Rivoltini L, Cassatella MA
Blood 2004 May 15;103(10):3837-44

---

TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors.

Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, Andera L, Stopka T
Leukemia 2002 Jan;16(1):67-73

Immunocytochemistry

Supportive validation

Submitted by

Enzo Life Sciences (provider)

Main image

Experimental details

Apoptosis induced in Jurkat T leukemia cells by KillerTRAILTM (Prod. No. ALX-201-073) is completely blocked by mouse MAb to TRAIL (human) (2E5)Ê(Prod. No. ALX-804-296) in a concentration range of 0.5-1.5µg/ml. Concentration of MAb 2E5 required for inhibition may vary depending of the cell type studied and the concentration of soluble recombinant human TRAIL used. The neutralizing activity of MAb 2E5 has been confirmed with various sources of soluble recombinant human TRAIL including KillerTRAILTM. Method: Jurkat cells (5x104) were treated with KillerTRAILTM (300ng/ml) in the presence or absence of the MAb to TRAIL (human) (2E5) or a control IgG1 mouse monoclonal antibody. After 16 hours apoptosis was evaluated by forward/sideward scatter (FSC/SSC) combined with propidium iodide (PI) staining analyzed by flow cytometry.

Supportive validation

Submitted by

Enzo Life Sciences (provider)

Main image

Experimental details

Ê MAb to TRAIL (human) (2E5) (Prod. No. ALX-804-296) can be used to detect surface human TRAIL in transiently transfected 293T cells in flow cytometry as well on untransfected cells expressing endogenous surface TRAIL. Method: 293T cells (10cm dishes) were transfeced with 0, 1, or 15µg plasmid coding for full length human TRAIL for 24 hours using a standard calcium phosphate transfection method. All dishes were cotransfected with 1µg plasmid coding for EGFPas a cotransfection marker. Viable cells (FSC/SSC region R1), that were GFP-positive (transfected) (FL1 region R3) were analyzed with respect to surface expression of human TRAIL. Cells were stained with MAb to TRAIL (human) (2E5) as well as with an isotype-matched control (control IgG1) at 10µg/ml.Ê Binding of the primary MAbs is detected using RPE conjugated goat anti-mouse IgG (FL2).

Supportive validation

Submitted by

Enzo Life Sciences (provider)

Main image

Experimental details

Neutralizing effect of MAb to TRAIL (human) (2E5) on TRAIL-induced apoptosis (TRAIL, Soluble (human) (recombinant) Set (Prod. No. ALX-850-018); containing Enhancer for Ligands).